User:Doc James/RfC

Clarification of RfC
Should we state " Simvastatin is relatively low cost." at the end of the 4 paragraph of the simvastatin article.

Based on this 2012 article which states "Simvastatin... is a universally accepted and relatively inexpensive drug."

And this 2018 review which states "The U.S. patent for simvastatin held by Merck expired on June 23, 2006, which catalyzed a large generic drug launch, with firms from India and Israel ramping up production (18). Costs fell from $1,200 to $40/patient/year, as priced by the Management Sciences for Health International Medical Products Price Guide (19). This reduction helped make statins cost-effective by WHO standards, and in 2007, statins were added to the EML as a therapeutic class. Given its lower cost and off-patent status, we proposed simvastatin as the representative example of the therapeutic class of statins. In 2007, statins were added to the EML with simvastatin as the representative."

Support

 * Support as proposer. The 2018 review makes it clear why the relatively low cost of this medication is notable. Doc James  (talk · contribs · email) 21:31, 30 March 2020 (UTC)

Discussion

 * Everyone is to put their discussion in their own section.